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Does neuronal loss associated with dementia necessarily impair the ability to learn new 
information and recall old memories? In a recent report in Nature, Fischer et al. (2007) 
show that the ability to learn and remember can be reestablished in a mouse model of 
dementia through either environmental enrichment or chronic treatment with an inhibitor 
of histone deacetylase.A major focus of neurodegenerative 
disease research is identifying the 
molecules and processes mediating 
neuronal loss. Several neurodegen-
erative diseases have been associ-
ated with dysfunction of a cyclin/
cyclin-dependent kinase complex 
cdk5/p25, including Alzheimer’s dis-
ease and Parkinson’s disease. Stud-
ies examining the effect of inducible 
overexpression of p25 have provided 
a functional link between cdk5/p25-
associated neurodegeneration and 
cognitive performance (Fischer et al., 
2005). More importantly, these stud-
ies established a powerful mouse 
model of inducible neurodegenera-
tion. A recent study by Fischer et al. 
(2007), reported in Nature, exploits 
this system to ask a compelling ques-
tion: does neurodegeneration result 
in a permanent loss of learning and 
memory? Remarkably, the answer is 
not necessarily.
As in an earlier study, Fischer et al. 
(2007) demonstrate that overexpres-
sion of p25 results in neurodegenera-
tion and cognitive deficits. Moreover, 
chronic overexpression of p25 affects 
both learning and memory, mirroring 
the cognitive deficits observed in 
many dementias, including Alzheim-
er’s disease. Surprisingly, the deficits 
in both learning and memory recall 
were completely recovered by pro-
longed exposure (4 weeks) to either 
an enriched environment or sodium butyrate, a histone deacetylase 
inhibitor. Recovery of cognitive per-
formance correlated with an increase 
in the number of synapses, but not 
neurons. This last point is striking as 
it dissociates loss of neuronal somata 
with cognitive performance. Collec-
tively, these results indicate that cog-
nitive performance is a function of 
synaptic connectivity and that treat-
ments that enhance connectivity may 
enhance cognitive performance.
The report by Fischer et al. (2007) 
stimulates many questions regard-
ing the site of action and mechanism 
of the treatments that promote the 
recovery of cognitive function in the 
face of neurodegeneration. First, it 
would be interesting to determine 
whether systemic administration of 
sodium butyrate activated the same 
processes as environmental enrich-
ment. One consequence of continual 
environmental enrichment is induc-
tion of increased locomotor behavior 
due to exploration of the novel objects 
placed in the rodent’s environment. 
Thus, the effects of environmental 
enrichment may include an exercise 
component that would not be present 
in the animals treated with sodium 
butyrate. The recovery of cogni-
tive function by either environmental 
enrichment or sodium butyrate was 
correlated with a general increase in 
acetylation and/or methylation of his-
tone tails. Both environmental enrich-Cell 12ment and systemic administration 
of sodium butyrate affect the entire 
brain, but the specific cells where 
changes in histone modifications 
occurred were not determined. This 
is especially important as the neu-
rodegeneration that occurs in these 
mice is accompanied by apparent 
gliosis, the proliferation of astrocytes 
at sites of damage (Cruz et al., 2003). 
This suggests that glia could be a 
target of these treatments in addition 
to neurons. Moreover, the changes 
in histone acetylation and meth-
ylation observed are consistent with 
increases in transcription, but the 
identity of the relevant genes affected 
by either environmental enrichment or 
HDAC inhibition remains to be deter-
mined. Recent evidence suggests 
that the transcription factor CREB is 
essential for HDAC inhibitor-medi-
ated cognitive enhancement (Vecsey 
et al., 2007), and a previous study 
suggests that environmental enrich-
ment increases CREB immunoreac-
tivity in the hippocampus (Williams 
et al., 2001). It would be interesting 
to determine whether CREB and the 
expression of CREB target genes, 
such as the orphan nuclear receptor 
nur77, are required for the recovery of 
cognitive function in the mouse model 
used by Fischer et al. (2007).
The study by Fischer et al. (2007) 
highlights the potential clinical util-
ity of HDAC inhibitors as agents to 9, June 1, 2007 ©2007 Elsevier Inc. 851
Figure 1. Cognitive Recovery after Neurodegeneration
Shown is a simple network of neurons representing the various stages of information flow relevant to learning and memory. Information 
from the environment must first be received and encoded. Once encoded, the information must be stored for later recall and behavioral 
modification.
(A) Overexpression of p25 results in loss of neurons and synapses involved in recall of previously stored information. Exposure to environmental 
enrichment or sodium butyrate therapy results in growth of new synapses and restoration of a critical number of synaptic connections between 
neurons involved in storage and recall to allow access to memories.
(B) Overexpression of p25 results in loss of neurons and synapses involved in storage of information. In this model, information is stored in 
a highly redundant fashion at synapses across several neurons. Therefore, loss of a neuron does not result in complete loss of information. 
Exposure to environmental enrichment or sodium butyrate therapy results in sprouting of new synapses and restoration of access to previ-
ously stored memories.enhance cognition. In rodent mod-
els, HDAC inhibitors enhance syn-
aptic plasticity and learning, amel-
iorate symptoms of Rubinstein Taybi 
Syndrome (a disorder character-
ized by mental retardation), prevent 
neurodegeneration associated with 
Huntington’s disease, and act as 
an antidepressant (Ferrante et al., 
2003; Levenson and Sweatt, 2005; 
Tsankova et al., 2006). Chronic 
treatment with sodium butyrate sig-
nificantly increased the number of 
synapses, suggesting that one pos-
sible effect of chronic therapy was 
enhanced expression of neurotrophic 
factors in the brain.
Restoration of memory after addi-
tion of synapses suggests two mod-
els for how environmental enrich-
ment and sodium butyrate therapy 
might rescue cognitive perform-
ance. It should be noted that neither 
model is mutually exclusive, and it 
is likely that some combination of 852 Cell 129, June 1, 2007 ©2007 Elseviethe two may have occurred in the 
experiments reported by Fischer et 
al. (2007). First, overexpression of 
p25 may have selectively eliminated 
synapses and neurons involved in 
information transfer in the brain 
(Figure 1A). This could be as simple 
as connecting a “storage” neuron 
to a “conscious readout” neuron or 
as complex as inhibiting oscillatory 
behavior involved in synchroniz-
ing disparate regions of the brain. 
The second possibility is that over-
expression of p25 results in loss 
of neurons involved in information 
storage (Figure 1B). For recovery 
to be possible, information must be 
distributed across a network of syn-
apses in a highly redundant fashion, 
and the brain must have the ability 
to recapitulate the state of a net-
work of synapses when presented 
with new nodes for storage. For the 
distributed network model to explain 
the data reported by Fischer et al. r Inc.a critical amount of redundancy 
must be present before informa-
tion can be consciously accessed. 
Disruption of the ability to access 
stored information or the ability to 
store information altogether would 
manifest as an inability to learn 
and remember, just as reported by 
Fischer et al.
The study by Fischer et al. repre-
sents a true breakthrough on many 
fronts, but perhaps the most impor-
tant realization of this study is that 
neurodegeneration does not neces-
sarily equate to a decline in cogni-
tive performance. The adult brain 
appears to possess a degree of 
plasticity not previously appreciated 
or clinically exploited. Moreover, pre-
vention of age-associated cognitive 
impairment or even recovery from 
traumatic brain injury or unexplained 
neurodegeneration might be as sim-
ple as daily enrichment of your life, 
or as easy as a pill.
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DAP kinase 1 (DAPK1) as a can-
didate gene silenced in all cases 
of CLL. Epigenetic silencing of 
DAPK through promoter methyla-
tion occurred in almost all sporadic 
cases of CLL. Furthermore, in a 
large family with several affected 
individuals, a mutation/polymor-
phism in the promoter of DAPK1 
was identified as causing persistent 
downregulation of DAPK1 expres-
sion due to increased binding of the 
HOXB7 transcriptional repressor. 
This study identifies a single gene 
as being affected by genetic and 
epigenetic alterations in each case 
of CLL analyzed and provides evi-
dence for the genetic susceptibility 
of this disease.
Several functions for DAPK1 in 
differentiation and cell death have 
been described (Bialik and Kimchi, 
2006). Initially, DAPK was cloned 
as a serine/threonine kinase asso-
ciated with the cytoskeleton and 
identified as a mediator of cell death 
induced by interferon γ. DAPK1 is 
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